A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine
A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine
The purpose of the study is the measure the levels of lasmiditan in the body of children aged
 6 to 17 with migraine. The study also will also examine the safety and tolerability of
 lasmiditan in children aged 6 to 17 with migraine.

 The study will last about 6 weeks, and includes 4 visits.
Inclusion Criteria:

 -  Participants must have a history of migraine headaches for more than 6 months

 -  Participants must have a history of 2 to 15 migraine headaches per month in the past 2
 months

 -  Participants must weigh between 15 and 55 kilograms (kg)

 -  Participants must not have a migraine headache on the day of lasmiditan administration

 Exclusion Criteria:

 -  Participants must not be pregnant or nursing

 -  Participants must not have any acute, serious, or unstable medical condition

 -  Participants must not be actively suicidal or at significant risk for suicide, in
 the opinion of the investigator

 -  Participants must not be on a medicine that acts in the brain and spinal cord